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Abstract
Background: Cancers related to tobacco use and African-American ancestry are under-characterized by genomics.
This gap in precision oncology research represents a major challenge in the health disparities in the United States.
Methods: The Precision Oncology trial at the Wake Forest Baptist Comprehensive Cancer Center enrolled 431
cancer patients from March 2015 to May 2016. The composition of these patients consists of a high representation
of tobacco-related cancers (e.g., lung, colorectal, and bladder) and African-American ancestry (13.5%). Tumors
were sequenced to identify mutations to gain insight into genetic alterations associated with smoking and/or
African-American ancestry.
Results: Tobacco-related cancers exhibit a high mutational load. These tumors are characterized by high-frequency
mutations in TP53, DNA damage repair genes (BRCA2 and ATM), and chromatin remodeling genes (the lysine
methyltransferases KMT2D or MLL2, and KMT2C or MLL3). These tobacco-related cancers also exhibit augmented
tumor heterogeneities. Smoking related genetic mutations were validated by The Cancer Genome Atlas dataset that
includes 2,821 cases with known smoking status. The Wake Forest and The Cancer Genome Atlas cohorts (431 and
7,991 cases, respectively) revealed a significantly increased mutation rate in the TP53 gene in the African-American
subgroup studied. Both cohorts also revealed 5 genes (e.g. CDK8) significantly amplified in the African-American
population.
Conclusions: These results provide strong evidence that tobacco is a major cause of genomic instability and
heterogeneity in cancer. TP53 mutations and key oncogene amplifications emerge as key factors contributing to
cancer outcome disparities among different racial/ethnic groups.
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Introduction
Advances in genomics and informatics have
validated the importance of individuality in cancer
diagnosis and treatment. Evidence illustrates that
cancer is a disease of genetic and epigenetic causality,
profoundly affected by environment and lifestyle [1].
An increasing number of genetic alterations have been
characterized that drive the pathogenesis of cancer
and convey therapeutic actionability [2]. These driver
mutations often are not restricted to a specific cancer
type, histology or patient demographic. This
unprecedented
molecular
understanding
of
individual cancers has ushered in a new era of health
care coined precision medicine [3].
Precision medicine has begun a reprogramming
of clinical oncology practice [4, 5]. Specialization in
organ-oriented disease is being supplemented with
molecular target assessment and targeted treatment
across cancer types [6-9]. New clinical trial models
(e.g., BASKET trial, NCI-MATCH) emphasize
treatment decisions based on druggability of gene
mutations rather than tumor histology [10, 11].
Precision medicine consortia have formed to test this
new mode of cancer management [12]. The Precision
Medicine Exchange Consortium (PMEC) is one such
consortium, consisting of eight major cancer centers in
the US, including the Wake Forest Baptist
Comprehensive Cancer Center (WFBCCC).
To investigate the relationship between precision
medicine-derived cancer genomic correlates and
patient demographics at WFBCCC, 431 cancer
patients were enrolled into the Wake Forest Precision
Oncology Initiative trial. This patient cohort reflects
the patient population in the WFBCCC catchment
area with a high representation of tobacco-related
cancers (e.g., lung, colorectal, and bladder) and
African American (AA) ancestry (13.5%). In the
WFBCCC catchment area, (22% of adults are current
tobacco users versus 19% nationally). Cigarette smoke
is a known carcinogen, causing defined mutational
signatures [13, 14]. However, smoking-related genetic
changes in cancer are not well-characterized. Even
more unclear is whether the mutational events differ
between AA and Caucasian cancer patients, despite
AA cancer patients having a poorer prognosis,
including cancer-related and higher overall mortality
rates [15].
Here, we report the characterization of the
mutational landscapes of our unique cohort of cancer
patients with findings validated in The Cancer
Genome Atlas (TCGA) dataset. We also provide
examples of mutation directed treatment in these
patients to demonstrate the clinical impact of
precision oncology initiatives.
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Material and Methods
Patient Cohort
Four hundred thirty-one cancer patients from
the catchment area of the WFBCCC participated in the
IRB-approved Wake Forest Precision Oncology
Initiative (POI) from March 1, 2015 to May 30, 2016.
African American status is based on self-reported
ancestry. Each patient was consented for research
analysis of sequencing results. Tumor specimens were
evaluated by two board-certified pathologists to
confirm diagnosis and classification. Tumor biopsies
and surgical specimens were formalin-fixed and
paraffin-embedded
immediately
following
acquisition, according to standard clinical protocol.
Tumor blocks of sufficient cellularity (>20%) and
limited necrosis were selected and submitted to
Foundation Medicine for FoundationOne® testing.
The clinical management process is shown in Figure
S1 and supplementary methods. ClinicalTrials.gov
Identifier: NCT02566421

Genomic Profiling
Tumor tissue was subjected to Next Generation
Sequencing
(NGS)
to
identify
mutations,
rearrangements and copy number alterations
spanning 415 cancer-related genes that make up the
FoundationOne ® (F1) test (Foundation Medicine,
Cambridge, MA) (Supplementary Methods) [16].

Statistical and Bioinformatic Analysis
Nonsynonymous somatic mutation calls were
quantified. Patients were assigned to low or high
mutation load groups based on the cohort mean
mutation number. Fisher’s exact test and
Benjamini-Hochberg multiple testing adjustments
were used to determine associations between
mutation load and DNA damage genes and
chromatin remodeling genes. Smoking status was
defined by self-reported smoking history obtained
from Cancer Registry and/or Epic Electronic Medical
Record. Never smokers were defined as respondents
who smoked less than 100 cigarettes in their lifetime.
Based on evidence that smoking cessation reduces
cancer risk by half at five years, active smokers at the
time of clinical data collection and those who had quit
smoking within the previous five years were
considered current/recent smokers [17, 18]. Those
having quit more than five years prior to data
collection were defined as former smokers. Only
white (Caucasian) and black (AA patients) were
included in disparities analyses, as these are the two
main ethnic groups of the WFBCCC catchment area.
Other racial/ethnic populations were underrepresented in the sample (less than 5%). Analyses for
http://www.thno.org
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discovery of smoking-related mutations focused on
genes with functional roles in DNA Damage Repair
and Chromatin Remodeling. Each set of analyses used
the Cochran-Mantel- Haenszel test to uncover
associations between smoking status (defined as an
ordinal variable – Never, Former, Recent) and gene
mutation. Fisher’s exact test was used to assess
significance (p < 0.05) of gene mutation frequencies
that differed with respect to low and high mutation
load and racial status (Caucasians versus AA). The
Hochberg (1988) approach was used to adjust for
multiple testing [19]. MutSig algorithm, MutSigCV,
was used to evaluate the significance of mutated
genes. All analyses were performed with R statistical
computing software version 3.3.0 [20]. Mutagenic
processes and tumor clonality were analyzed with R
packages
somaticSignatures
and
SciClone,
respectively (Supplementary Methods) [21].

Results
Mutational Analysis
We analyzed 431 cancer patients from the
catchment area of the WFBCCC that participated in
the IRB-approved Wake Forest Precision Oncology
Initiative
(POI).
Patient
demographics
are
summarized in Table 1, Table S1 and Figure 1. In our
patients, the most frequently mutated genes were
tumor suppressor genes TP53, APC, FAT1, RB1,
BRCA2, and NF1; Wnt signaling pathway genes
LRP1B and APC; oncogenes KRAS, PIK3A, DNA
damage repair (DDR) genes (ATM, BRCA2);
chromosomal integrity genes (TERT), and chromatin
remodeling (CR) genes (KMT2D or MLL2, KMT2C or
MLL3, ARID1A, ARID1B, EP300) (Figure 2A).
Some of the observed gene mutations were
expected. For example, TP53 showed a uniformly
high frequency of mutation across all cancer types
while APC was predominantly mutated in colorectal
cancer. KRAS was mutated at high frequency in
pancreatic, colorectal, and lung cancer. LRP1B was
frequently mutated only in lung cancer (43 of 90,
47.8%). Another gene highly mutated in lung cancer
was SPTA1 (33 of 90, 37%) that has unknown
oncogenic functions. Analysis of The Cancer Genome
Atlas (TCGA) lung cancer cohort (adenocarcinomas
and squamous) validated the frequent mutation of
SPTA1 gene (Figure S2). EPHA3 and EPHA5 were also
frequently mutated in both our and TCGA cohorts
(Figure S2). TERT, which codes for telomerase and is
involved in the longevity of tumor cells, was found to
be frequently mutated at a promoter hot spot (-124C >
T) in brain tumors (16 of 31, 53%), bladder cancers (9
of 16, 56%), and head/neck cancers (6 of 26, 23%),
consistent with recent reports [22, 23]. In contrast, the
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TERT promoter is rarely mutated in colorectal, lung or
pancreatic cancer, or soft tissue sarcoma (Figure 2B).
Table 1. Demographics of patients (N = 431) in the Precision
Oncology Initiative
Characteristic
SMOKING HISTORY
Current
Former
Never
RACE
White or Caucasian
Black or African American
American Indian or Alaska Native
Asian
Native Hawaiian or Pacific Islander
Other
ETHNICITY
Hispanic or Latino
Not Hispanic or Latino
CANCER STATUS
Metastasis
Primary
Unknown
DISEASE STAGE
Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
Undetermined/Unknown
TUMOR TYPE
Lung
Colorectal
Other
Cup
Brain
Sarcoma
Head/Neck
Other GI
Breast
Bladder
Pancreas
Ovary/Uterus
Appendix
Kidney
Prostate

No. (%)
127 (29.5)
145 (33.6)
159 (36.9)
356 (82.6)
58 (13.5)
2 (0.5)
5 (1.2)
1 (0.2)
9 (2.1)
8 (1.9)
423 (98.1)
185 (42.9)
220 (51.0)
26 (6.0)
2 (0.5)
31 (7.2)
36 (8.4)
85 (19.7)
231 (53.6)
46 (10.7)
90 (20.9)
56 (13.0)
43 (10.0)
41 (9.5)
31 (7.2)
30 (7.0)
26 (6.0)
21 (4.9)
18 (4.2)
16 (3.7)
16 (3.7)
14 (3.2)
10 (2.3)
10 (2.3)
9 (2.1)

A striking observation was the remarkably high
mutation rates of DDR and CR genes in our cohort
and their association with high-mutational load
(Figure 3A, B, C), underscoring the highly unstable
genome associated with smoking-related cancers that
dominate our cohort.
Large
numbers
of
gene
mutations
(hypermutation phenotype) and copy number
alterations (chromosomal instability or CIN)
represent two different types of genomic instability
[24]. We observed that the CIN phenotype exhibited
variable patterns in different cancer types, with
extensive overall changes in lung and colorectal
cancers (Figure S3A). Despite high mutation rates,
two smoking-related cancer types, bladder and
http://www.thno.org
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head/neck cancers, did not show extensive copy
number alterations (Figure 3C, Figure S3A). Among
the most extensively amplified genes were oncogenes,
including ERRB2, MYC, MET, CDK6, and EGFR (e
Figure 3B). Two cases exhibited amplification of
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immunosuppressing genes PD-L1 (CD274) and PD-L2
(PDCD1LG2), suggesting a role for anti-PD-1 or
anti-PD-L1 therapy. Genes frequently deleted in our
advanced cancer cohort are CDKN2A/B and PTEN
(Figure S3B).

Figure 1. Patient Demographics. (A) Patient smoking status within the context of type of cancer. (B) Patient race as described within cancer type. (C). Gender
of patients within each cancer type.

http://www.thno.org
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Figure 2. Global Landscape of Somatic Mutations. (A) Global somatic mutational landscape of all patients for the top 30 genes having the largest fraction of
mutations. Top and left bar charts show the number of mutations and percent of mutated samples, respectively. The lower part of panel A summarizes clinical
information from each patient. (B) Somatic mutational landscape for major cancer groups for the same 30 genes seen in (A). Cancer group-wise mutational patterns
show large similarities (TP53) but also striking differences (KRAS, APC, TERT) between cancer groups.

http://www.thno.org

Theranostics 2017, Vol. 7, Issue 11

2919

Figure 3. Associations between DDR/CR Gene Mutation Frequency, Tumor Mutational Load and Smoking Status. DDR and CR genes are mutated
at higher frequency (A) and in tumors with higher mutation load (B). High and low mutational load (ML) designations are based on above-mean (orange) and
below-mean (light green) mutation count, respectively. Nonsynonymous protein-altering mutations (SNVs, in/dels, rearrangements) and copy number deletions were
included. **** (p < 0.0001); *** (p < 0.001); ** (p < 0.01); * (p < 0.05), Fisher’s exact test and Benjamini-Hochberg adjusting. (C) Mutational load across cancer groups
as a function of smoking status. Boxes mark the interquartile range (25th-75th percentile) of the distribution while the whiskers demarcate the 5th and 95th percentiles.
The white line marks the median of the distribution.

Gene Mutations Associated with Smoking
In our cohort, proportions of smokers were
similar in AAs and Caucasian-Americans (38 of 58,
216 of 356, respectively; Fisher exact test p-value,
0.56).
Current/recent
smokers
exhibited
a
significantly higher mutational load (mean = 20.5,
median = 14.0) than former smokers (mean = 13.0,
median = 11.5; p = 0.017, 2-sided t-test) and never
smokers (mean = 12.3, median = 11.0; p = 0.029,
2-sided t-test). Analysis of total mutations per cancer
showed a heterogeneous pattern (Figure S4) with
lung, bladder, and colorectal cancer exhibiting high
tumor mutational load. Appendiceal, brain, and
prostate cancers exhibited the lowest mutational load.
Analysis of the mutational signatures

characterized by nucleotide changes in the context of
neighboring nucleotides identified three major
signatures (Figure 4A). Current smokers, former
smokers and never smokers exhibited distinct
mutational signatures (Figure 4B). Many DDR and CR
genes exhibited associations with smoking status
(Figure 4C), with a greater frequency of mutation in
current/recent or former smokers as compared to
never smokers. After adjusting for multiple testing,
mutations in two DDR genes – CDK12 and BRCA2
met the criteria for statistical significance (p = 0.0069
and 0.016, respectively). Similarly, the CR gene
KMT2D met the criteria for statistical significance (p =
0.0087), while two others (KDM6A and SMARCA4)
were nominally significant (p = 0.026 and 0.032,
respectively) (Figure 4C, Table S2).
http://www.thno.org
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Figure 4. Association of Gene Alterations and Smoking. (A) Three somatic mutational signatures present in the cohort. X-axis consists of adjacent nucleotides to the
mutated base indicated on top of each column. Y-axis describes strength of contribution for a given triplet formed of altered base and adjacent nucleotides. (B) Contribution of
each signature to smoking categories. (C) Significant smoking related alterations in DNA damage repair (DDR) and chromatin remodeling (CR) genes defined by the
Cochran-Mantel-Haenzel test. (D) Validation for the smoking associated mutations in TCGA data. The validation dataset consists of 675 current smokers, 1351 former smokers
and 795 never smokers. (E) Significant association between high tumor clonality and smoking. * (p < 0.05), ** (p < 0.01)

To begin validation in the TCGA cohort we
found that among the solid tumors, mutation and
smoking status data was available in 2,821 cases. As
shown in Figure 4D, current and former smokers have
similar mutation frequencies of these genes. This
analysis showed that most smoking-related gene
mutations found in our cohort (e.g., KMT2D, BRCA2)
were validated in the TCGA cohort.
Intratumoral clonal heterogeneity poses serious
challenges to precision oncology treatment [25].
Tumors comprised of multiple clones with different
mutational events may require multiple targeting
strategies; in combination or in sequence. We
quantified tumor clonal heterogeneity based on
clustering of variant allele fractions (Figure S5A, B,
see Methods). Mutation rates for 48% of patients were
relatively low with no clonal diversity. For the others,
19, 23, and 10% of cases exhibited 1, 2 or more than 2
clones, respectively, based on clonality analysis
(Figure S5C). Higher clonality was associated with
smoking (Figure 4E).

Gene Mutations Associated with Race
The overall mutational landscape of AA patients

is similar to that of the whole WFBCCC cohort, the
majority of which are Caucasian patients (Figure 5A
and Figure 2A). However, our analysis revealed
differential mutation rates in the key genes, TP53 and
KMT2C (Figure 5B). In the TCGA cohort, there are 842
AA and 7,149 Caucasian cases with mutation data and
892 AA and 7,679 Caucasians with gene amplification
data. TP53 (p = 0.027), and to a lesser extent, KMT2C
(p = 0.093), were more frequently mutated in AA
patients in the TCGA cohort (Figure 5C). Gene copy
number analysis revealed marked differences in five
oncogenes in our cohort (Figure 5D); all of them were
found to be more significantly amplified in AA in the
TCGA cohort (Figure 5E).

Precision Oncology Case Reports
The essence of precision oncology is to match
mutational information with drugs that have shown
therapeutic efficacy in targeting the mutated protein.
Oncologists at WFBCCC have designed clinical
treatment regimens based on genomics testing in our
Precision Oncology Trial and patients have shown
remarkable responses. Key examples are described in
Supplementary Material.
http://www.thno.org
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Figure 5. Association of Mutations with AA Population. (A) Mutational landscape in AA cancers, 30 most frequently mutated genes. (B) Mutation frequencies
among Caucasian and AA for significant race-associated genes. (C) Validation of TP53 mutation in AA in TCGA data. (D) Most common copy number alterations in
AA. Genes with significant difference after adjustment are marked with asterisk. (E) Genes with significant connection between race and alteration status validated
TCGA data are marked with asterisk * (p < 0.05), ** (p < 0.01), *** (p <0.001).

http://www.thno.org
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Discussion
Smokers and AAs are more prevalent among our
disproportionately rural, Appalachian/Piedmont
catchment area population. Thus, we are able to
uniquely interrogate mutations associated with these
two understudied populations. This undertaking has
provided a number of insights. Among the most
interesting discoveries are the revelations that DDR
and CR genes are highly mutated in current/former
smokers, and smoking is associated with augmented
clonal
evolution
(clonality)
and
tumor
heterogeneities. This is consistent with recent genomic
characterization of smoking related cancers [26].
These results provide strong evidence that genomic
instability is a fundamental hallmark of cancer and
the events underlying the regulation of genome
stability are centered on interactions with
environmental factors and lifestyle.
AA cancer patients have a more dismal
prognosis, which represents a key health disparity
challenge in the US. Our genomics analysis revealed a
number of genes mutated at different frequencies in
AA and Caucasian cancer patients. After further
analysis of the larger independent TCGA cohort,
mutations of the tumor suppressor gene TP53 still
emerged as a more common event in AA cancer
patients. Notably, in our cohort of lung cancer,
mutation rates for a number of genes including TP53
are higher than that observed in the TCGA cohort,
consistent with the predominance of advanced and
smoking-related cancers in our cohort. However, our
analysis showed that the enriched mutation in TP53 in
AA is not driven by lung cancer in the cohort because
TP53 mutation rates are similar in AA and Caucasian
Americans (p = 0.5). TP53 has long been recognized as
a critical control gene for genome stability [27].
Numerous studies have shown that mutations of
TP53 are associated with poor prognosis in cancer
[28]. Therefore, genomic stability regulated by TP53
may be a key factor that contributes to cancer outcome
disparities among different racial groups. The
limitation of this study is the size of cohort enrolled in
precision oncology initiatives due to the enrollment
criteria and cost associated with the clinical
sequencing tests. Therefore, future data sharing effort
will enable pooled analysis of all the major precision
oncology programs in the country to determine
whether genetic events such as increased TP53
mutation rates are observed in all major cancer types
and their relationship with smoking. Interestingly,
during the review of our study, a recent paper
focusing on lung cancer reported overall similar
mutation frequencies between AA and Caucasian
American, however they also observed more
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prevalent TP53 mutation in AA subgroup than
Caucasian group [29].
In addition to gaining insight into the knowledge
of genetic/molecular mechanisms of cancer
development/progression, a key benchmark for
precision oncology initiatives is the translatability of
genomics information to more accurately targeted
and beneficial treatments in patients [5, 30-33]. Several
successful examples at WFBCCC are reported here
and described in supplemental document.
There is no doubt that increasing numbers of
cancer patients will benefit from the precision
oncology design. There are, however, a number of
important challenges and limitations [34].
First, the current precision oncology initiatives
focus more on advanced metastatic cancer patients.
Many of these patients die within 3-4 months of the
genomic testing, before treatment decisions can be
rendered. Thus, genomic testing should extend to
patients with newly diagnosed metastatic disease,
with the hypothesis that a patient with longer
expected survival will benefit more from precision
treatment. Retesting of tumors from recurrent patients
will identify treatment-associated mutations to revise
therapeutic strategies. Secondly, drug availability is a
major problem [35-37]. Many FDA approved but
off-label drugs, are not covered by insurance. Getting
access to these off-label drugs on a compassionate
basis invariably requires the resources and extra time
of physicians. There clearly is a need for a streamlined
process of drug acquisition for precision oncology to
reach its full potential. Thirdly, genomic testing
reveals many gene mutations without information
about whether these mutations are deleterious (driver
mutations). Thus, there is a clear need for efficient
high throughput laboratory assays to identify
functional mutations [38]. Fourthly, intratumoral
heterogeneity poses a significant obstacle for
sustained treatment response to a single agent
therapy [25, 39]. Our clonality analyses showed that
different clones exist in a fraction of tumors with
different potential driver mutations. Therefore,
precision oncology requires an understanding of
tumor clonality to inform the design of combination
or sequential therapy with different drugs. Finally,
from the patients’ perspective, these complexities are
compounded by the psychosocial and ethical
considerations inherent to the genomic profiling
process [40, 41]. In this newly evolving paradigm,
patients and providers need to navigate care from a
patient-centered framework. In the decision making
process, smoking status and ethnicity should clearly
be considered because of the association with
differential mutation rates.

http://www.thno.org
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